AccuCheck Counting Beads are an efficient single-platform method for absolute cell counts that combines the advantages of direct flow cytometricRead more
Have Questions?
Catalog Number
Quantity
PCB100
10 mL
Catalog number PCB100
Price (MXN)
-
Quantity:
10 mL
AccuCheck Counting Beads are an efficient single-platform method for absolute cell counts that combines the advantages of direct flow cytometric immunophenotyping with the use of two different fluorescent beads (A and B beads). These two fluorospheres are used as a double internal standard for blood volume calculation. A known volume of AccuCheck Counting Beads is added to the same known volume of stained blood in a lyse-no-wash technique. The beads are counted along with cells. Since the concentration of beads is known, the number of cells per microliter (the absolute count) is obtained by relating the number of cells counted to the total number of fluorescent bead events. The cell number is then multiplied by the number of total fluorospheres per unit of volume. As the AccuCheck Counting Beads system contains two different fluorospheres in a known proportion, we can first assure the accuracy of the assay by verifying the proportion of both types of beads.
Contains 1 bottle of AccuCheck counting beads (10 mL). Store in refrigerator (2–8°C).
Frequently asked questions (FAQs)
I am using counting beads to count cells, but I cannot find the beads on my scatter plots. What do I do?
The first thing to do is check your threshold and see if it is set on forward scatter. If so, the beads are probably being excluded by the threshold. Reducing the threshold setting should reveal your beads.
I want to count my cells using flow cytometry. How do I do this?
Cell counting using flow cytometry can be accomplished by adding an internal microsphere counting standard to the flow cytometric sample. The number of reference beads that are collected reflects a known volume. This allows you to calculate cell concentration.
Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies.
Authors:Yi Z, Diz R, Martin AJ, Morillon YM, Kline DE, Li L, Wang B, Tisch R,
Journal:Diabetes
PubMed ID:22751694
Residual ß-cells found at the time of clinical onset of type 1 diabetes are sufficient to control hyperglycemia if rescued from ongoing autoimmune destruction. The challenge, however, is to develop an immunotherapy that not only selectively suppresses the diabetogenic response and efficiently reverses diabetes, but also establishes long-term ß-cell-specific tolerance ... More